Jack Azad, MD
General Practice · Los Angeles, CANPI 1841489440
Payments from drug & device makers
Across 1,434 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- AbbVie$4K
- Amgen$3K
- AstraZeneca$3K
- Alkermes, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- plus $15K from 51 others
What the payments were for
- Consulting fees$1,2003%
- Food & beverage$33,30196%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,537 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 421 | $549,118 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 269 | $447,448 |
| Xigduo XrDapaglifloz Propaned/Metformin | 234 | $327,703 |
| OzempicSemaglutide | 174 | $324,689 |
| FarxigaDapagliflozin Propanediol | 135 | $168,176 |
| EntrestoSacubitril/Valsartan | 97 | $165,585 |
| SynjardyEmpagliflozin/Metformin Hcl | 97 | $146,564 |
| EliquisApixaban | 181 | $140,928 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 80 | $94,720 |
| MounjaroTirzepatide | 34 | $86,020 |
| LinzessLinaclotide | 67 | $82,846 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $80,880 |
| JardianceEmpagliflozin | 74 | $75,342 |
| TrulicityDulaglutide | 29 | $48,816 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $44,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $4,824 | $549,118421 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $1,125 | $510,651462 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $711 | $450,629266 claims |
| Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr, Jentadueto, Combivent Respimat | $455 | $300,933237 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,881 | $212,787164 claims |
| NovartisEntresto | $594 | $165,58597 claims |
| PfizerEliquis | $2,389 | $140,928181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $739 | $134,83663 claims |
| GileadBiktarvy, Genvoya | $523 | $125,66433 claims |
| AbbVieLinzess | $3,502 | $82,84667 claims |
| MerckJanuvia, Janumet | $333 | $66,52565 claims |
| Alkermes, Inc.Lybalvi | $2,693 | $36,24320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Los Angeles
- Bruce TorkanLos Angeles$3.8M
- Abdi SameniLos Angeles$316K
- Enrique GonzalezLos Angeles$303K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Yang ChaiLos Angeles$150K
- Richard KimLos Angeles$97K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.